Antiviral monoclonal antibodies
- Name
- Antiviral monoclonal antibodies
- Accession Number
- DBCAT005730
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Ansuvimab A fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease. Casirivimab Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. Cilgavimab An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Imdevimab Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. Motavizumab Investigated for use/treatment in viral infection and pediatric indications. Nirsevimab A long-acting monoclonal antibody indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Palivizumab A monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients. Regdanvimab A monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19. Sipavibart A monoclonal antibody used to prevent COVID-19 in immunocompromised patients. Sotrovimab A monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization. Tixagevimab An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.